Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Alea Research Inc

Neither a doctor nor a teaching hospital

Research payments

$2,089,784

301 payments

Through program year 2025, Alea Research Inc is reported as receiving $2,089,784 in research payments, across 301 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $4,268 2
2024 Research $6,231 1
2023 Research $130,403 1
2022 Research $263,860 66
2021 Research $614,804 91
2020 Research $537,208 73
2019 Research $533,009 67

Breakdown

Who paid Research payments · program years 2019–2025
  1. Allergan Inc. $1,295,589 180 payments
  2. Teva Pharmaceuticals USA, Inc. $255,319 27 payments
  3. ITI, Inc. $158,664 29 payments
  4. Sage Therapeutics, Inc. $130,403 1 payment
  5. Otsuka Pharmaceutical Development & Commercialization, Inc. $70,117 4 payments
  6. Biohaven Pharmaceutical Holding Company Ltd. $53,135 34 payments
  7. Jazz Pharmaceuticals Inc. $49,205 4 payments
  8. Biohaven Pharmaceuticals, Inc. $44,327 15 payments
  9. ACADIA Pharmaceuticals Inc $13,500 4 payments
  10. AbbVie, Inc. $9,000 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. A Double-Blind, Placebo-Controlled Study of Cariprazine As Adjunctive Therapy in Major Depressive Disorder $491,928 32 payments
  2. A Double-Blind, Placebo-Controlled Study of Cariprazine As Adjunctive Therapy in Major Depressive Disorder $283,600 31 payments
  3. A Study to Evaluate the Safety, Tolerability, and Effect of Risperidone Extended-Release Injectable Suspension (TV-46000) for Subcutaneous Use as Maintenance Treatment in Adult and Adolescent Patients With Schizophrenia $255,319 27 payments
  4. A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, and Tolerability of Multiple Dosing Regimens of Oral Atogepant for the Prevention of Migraine in Patients With Episodic Migraine $143,587 15 payments
  5. A Phase 3, Open-Label, 1-Year Study of the Safety, Tolerability, and Need for Re-Treatment with SAGE-217 in Adult Subjects with Major Depressive Disorder $130,403 1 payment
  6. A Randomized, Double-Blind, Placebo-and Active-Controlled, Multicenter Study of Rapastinel as Monotherapy in Patients with Major Depressive Disorder $113,480 12 payments
  7. A Randomized, Double-Blind, Placebo-Controlled Multicenter Study to Assess the Efficacy and Safety of Lumateperone As Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder $107,637 14 payments
  8. A Randomized, Double-blind, Placebo-controlled, Multicenter Study of Rapastinel in the Prevention of Relapse in Patients with Major Depressive Disorder $88,352 17 payments
  9. A Randomized Double-Blind Placebo-Controlled Trial of Adjunctive Troriluzole in Obsessive Compulsive Disorder $70,609 27 payments
  10. A Double-Blind, Placebo-Controlled, Randomized Withdrawal,Multicenter Clinical Trial Evaluating the Efficacy, Safety, and Tolerability of Cariprazine in A Dose-Reduction Paradigm in Theprevention of Relapse in Patients With Schizophrenia $65,213 22 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record